Vaxzevria/COVID-19 Vaccine AstraZeneca: Risk of thrombosis in combination with thrombocytopenia - Updated information
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Vaxzevria (previously COVID-19 Vaccine AstraZeneca)
|
| Active substance |
ChAdOx1-SARS-COV-2
|
| Therapeutic area (MeSH) |
COVID-19 virus infection
|
| Procedure number |
EMEA/H/C/005675/II/0014
|
| Regulatory outcome |
Variation
|
| DHPC type |
Type II variation
|
| Human ATC code |
J07BX03
|
| Dissemination date |
02/06/2021
|